EP 209: Reinventing Fabry disease treatment with Chris Hopkins of Glafabra Therapeutics

<p>This week on The Genetics Podcast, Patrick is joined by Chris Hopkins, CEO of Glafabra Therapeutics. They discuss how Glafabra is advancing a next-generation cell therapy for Fabry disease, the differences between gene therapy modalities, and the future of cell and gene therapy innovation.</p><p><strong>Show Notes: </strong></p><p><strong>0:00 </strong>Intro to The Genetics Podcast</p><p><strong>00:59</strong> Welcome to Chris</p><p><strong>01:28</strong> Overview of Fabry disease and reviving a promising shelved gene therapy</p><p><strong>03:12 </strong>Limitations of current Fabry disease treatments versus Glafabra Therapeutics’ approach</p><p><strong>05:19</strong> How autologous cell therapy avoids an immune response</p><p><strong>06:43 </strong>Comparing this cell therapy approach to that of Casgevy for sickle cell disease</p><p><strong>11:28 </strong>Expanding Glafabra’s platform to other lysosomal storage disorders through enzyme cross-correction</p><p><strong>13:47 </strong>...